CMTA’s latest analysis reveals 135 genes and 169 subtypes driving CMT. It offers new insights into the complexity, classification, and future of genetic discovery. Read the story behind the headlines.
CMTA-STAR Partner Applied Therapeutics Presents 24-Month CMT-SORD Data at PNS 2025
CMTA-STAR Alliance Partner Applied Therapeutics presented 24-month Phase III data on govorestat for CMT-SORD at PNS 2025, showing sustained clinical benefit, MRI-based disease slowing, and continued safety. These findings support the potential for the first approved treatment for CMT-SORD and mark progress toward an expected NDA submission.
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
CMTA-STAR Alliance Partner NMD Pharma A/S has launched the SYNAPSE-CMT Phase II trial, with the first patient dosed at a CMTA Center of Excellence. This study is evaluating NMD Pharma's NMD670, an investigational therapy aimed at improving nerve-to-muscle communication in adults with CMT1 and CMT2. The trial is now enrolling at sites in the U.S. and Europe. Learn more about how CMTA supports this critical research and how you can get involved.
